RU2166320C2 - Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии - Google Patents

Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии Download PDF

Info

Publication number
RU2166320C2
RU2166320C2 RU95117068/14A RU95117068A RU2166320C2 RU 2166320 C2 RU2166320 C2 RU 2166320C2 RU 95117068/14 A RU95117068/14 A RU 95117068/14A RU 95117068 A RU95117068 A RU 95117068A RU 2166320 C2 RU2166320 C2 RU 2166320C2
Authority
RU
Russia
Prior art keywords
substituted
group
oxo
tetrahydro
hypertriglyceridemia
Prior art date
Application number
RU95117068/14A
Other languages
English (en)
Russian (ru)
Other versions
RU95117068A (ru
Inventor
Сугияма Ясуо
Юкимаса Хидефуми
Original Assignee
Такеда Кемикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Кемикал Индастриз, Лтд. filed Critical Такеда Кемикал Индастриз, Лтд.
Publication of RU95117068A publication Critical patent/RU95117068A/ru
Application granted granted Critical
Publication of RU2166320C2 publication Critical patent/RU2166320C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU95117068/14A 1994-10-07 1995-10-06 Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии RU2166320C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP06-244136 1994-10-07
JP24413694 1994-10-07

Publications (2)

Publication Number Publication Date
RU95117068A RU95117068A (ru) 1998-01-10
RU2166320C2 true RU2166320C2 (ru) 2001-05-10

Family

ID=17114301

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95117068/14A RU2166320C2 (ru) 1994-10-07 1995-10-06 Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии

Country Status (11)

Country Link
EP (1) EP0705607A2 (enrdf_load_stackoverflow)
KR (1) KR960013370A (enrdf_load_stackoverflow)
CN (1) CN1128657A (enrdf_load_stackoverflow)
AU (1) AU703422B2 (enrdf_load_stackoverflow)
CA (1) CA2160092A1 (enrdf_load_stackoverflow)
FI (1) FI954773A7 (enrdf_load_stackoverflow)
HU (1) HUT73422A (enrdf_load_stackoverflow)
NO (1) NO308580B1 (enrdf_load_stackoverflow)
NZ (1) NZ280165A (enrdf_load_stackoverflow)
RU (1) RU2166320C2 (enrdf_load_stackoverflow)
TW (1) TW401301B (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2271808C2 (ru) * 2001-06-06 2006-03-20 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция, включающая ингибитор липазы и жирнокислотный сложный эфир сахарозы

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862562B1 (en) * 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
DE69637603D1 (de) * 1995-09-13 2008-08-28 Takeda Pharmaceutical 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische Mittel
AU3481497A (en) * 1996-06-11 1998-01-07 Zonagen, Inc. Chitosan drug delivery system
WO1998047882A1 (en) 1997-04-21 1998-10-29 Takeda Chemical Industries, Ltd. 4,1-benzoxazepines, their analogues, and their use as somatostatin agonists
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
MXPA02003122A (es) 1998-03-31 2004-04-21 Inst For Pharm Discovery Inc Acidos indolalcanoicos substituidos.
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
EP1183242A2 (en) 1999-05-26 2002-03-06 Du Pont Pharmaceuticals Company 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
JP2003506440A (ja) * 1999-08-05 2003-02-18 プレサイエント ニューロファーマ インコーポレイテッド 中枢神経系に関連する疾患の処置のための１，４−ジアゼピン誘導体
EP1332763A4 (en) * 2000-11-09 2007-03-14 Takeda Pharmaceutical HIGH DENSITY AGENT Raising LIPOPROTEIN-CHOLESTEROL RATE
KR20040100835A (ko) 2001-02-15 2004-12-02 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
WO2003002147A1 (fr) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
WO2004067008A1 (ja) * 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited 受容体作動薬
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
EP1776096A2 (en) * 2004-08-09 2007-04-25 Takeda Pharmaceutical Company Limited Crp lowering agent
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
KR20080059233A (ko) 2005-10-21 2008-06-26 노파르티스 아게 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
KR20100017766A (ko) 2007-05-10 2010-02-16 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤조-1,4-디아제핀 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 이의 용도
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CA3179700A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CA3179702A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
IL311444A (en) 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153190A (en) * 1990-03-08 1992-10-06 Adir Et Compagnie Pyrrolo [1,2A] thieno [3,2-F] [1,4] diazepines
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
EP0579222A2 (en) * 1992-07-17 1994-01-19 Senju Pharmaceutical Co., Ltd. Lipid metabolism improving composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48855A1 (en) * 1992-04-20 1998-05-18 Takeda Chemical Industries Ltd 4,1-benzoxazepin derivatives and their use
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
WO1995021834A1 (en) * 1994-02-09 1995-08-17 Takeda Chemical Industries, Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5153190A (en) * 1990-03-08 1992-10-06 Adir Et Compagnie Pyrrolo [1,2A] thieno [3,2-F] [1,4] diazepines
EP0579222A2 (en) * 1992-07-17 1994-01-19 Senju Pharmaceutical Co., Ltd. Lipid metabolism improving composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Машковский М.Д. Лекарственные средства. - М.: Медицина, 1986, ч.2, с.90. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2271808C2 (ru) * 2001-06-06 2006-03-20 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция, включающая ингибитор липазы и жирнокислотный сложный эфир сахарозы

Also Published As

Publication number Publication date
AU703422B2 (en) 1999-03-25
NO953961D0 (no) 1995-10-05
EP0705607A3 (enrdf_load_stackoverflow) 1996-05-08
TW401301B (en) 2000-08-11
NO308580B1 (no) 2000-10-02
CN1128657A (zh) 1996-08-14
NO953961L (no) 1996-04-09
FI954773A0 (fi) 1995-10-06
HUT73422A (en) 1996-07-29
AU3308195A (en) 1996-04-18
FI954773A7 (fi) 1996-04-08
KR960013370A (ko) 1996-05-22
EP0705607A2 (en) 1996-04-10
NZ280165A (en) 1997-07-27
CA2160092A1 (en) 1996-04-08
HU9502918D0 (en) 1995-11-28

Similar Documents

Publication Publication Date Title
RU2166320C2 (ru) Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии
EP0862562B1 (en) Benzoxazepine compounds, their production and use as lipid lowering agents
US20080132483A1 (en) Agent for preventing or treating organ functional disorders and organ dysfunction
EP0645377B1 (en) Benzoxazepine derivatives useful as squalene synthetase inhibitors
CA2231052C (en) Benzoxazepine compounds, their production and use as lipid lowering agents
EP0567026A1 (en) 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides
JPWO2007102531A1 (ja) 併用薬
US20080058310A1 (en) High-density lipoprotein-cholesterol level elevating agent
US20090209510A1 (en) Novel Method of Treating Hyperlipidemia
US20080113965A1 (en) Skeletal muscle protecting agent
JP3479796B2 (ja) ベンゾオキサゼピン化合物
JP4138299B2 (ja) 高密度リポタンパク−コレステロール上昇剤
JPH08157369A (ja) トリグリセライド低下剤
US20090118255A1 (en) Crp Lowering Agent
JPH0987260A (ja) 縮合環化合物とその用途
JP4021612B2 (ja) ベンゾオキサゼピン化合物
RU2170732C2 (ru) Производные 4,1-бензоксазепина
JP3764180B2 (ja) 縮合環化合物とその用途
JP2004315500A (ja) 骨格筋保護剤
JP2007332154A (ja) ベンゾオキサゼピン化合物
KR20080015395A (ko) 황색종 치료제